Please login to the form below

Not currently logged in
Email:
Password:

Hikma

This page shows the latest Hikma news and features for those working in and with pharma, biotech and healthcare.

Advair generics and acquisitions to hit GSK in 2019

Advair generics and acquisitions to hit GSK in 2019

Novartis’ Sandoz and Hikma/Vectura are set to follow, after delays to the entrants because of the complexity of creating a close copy of GSK’s inhaler.

Latest news

More from news
Approximately 6 fully matching, plus 27 partially matching documents found.

Latest Intelligence

  • The human perspective The human perspective

    Chief among these moves were the German company's exit from the generics business, via a $2.6bn deal with specialty firm Hikma, and its forthcoming asset swap with Sanofi.

  • Deal Watch table for May 2014 Deal Watch table for May 2014

    348. Bedford Labs (Boehringer Ingelheim) / Hikma. Asset / product acquisition.

  • Pharma deals during May 2014 Pharma deals during May 2014

    Hikma, the Jordanian generic company, acquired the assets of the US-based Bedford Labs (owned by Boehringer Ingelheim), a generic injectable manufacturer, for $300m (16 x sales). The price consists of

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • BMS appoints new commercial leader, Davies joins Eisai and more BMS appoints new commercial leader, Davies joins Eisai and more

    Hikma Pharmaceuticals appoints VP, sales and marketing, Generics. Kristy Ronco has been appointed as vice president, sales and marketing, generics for Hikma Pharmaceuticals. ... Ronco joins Hikma after more than a decade at Zydus Pharmaceuticals, where

  • Sigurdur Olafsson becomes CEO of Hikma Sigurdur Olafsson becomes CEO of Hikma

    As chief executive officer, Olafsson will take responsibility for the effective development and execution of Hikma’s corporate strategy, focusing on opportunities to accelerate growth of the global business. ... Said Darwazah, Hikma’s recently

  • Hikma appoints group scientific officer and global head of R&D Hikma appoints group scientific officer and global head of R&D

    Dr Surendera Tyagi joins the pharma group from Fresenius Kabi. Speciality pharmaceutical group Hikma has appointed a group scientific officer and gloval head of R&D in the form of Dr ... Surendera Tyagi, who will focus on the group’s non-injectables

More from appointments
Approximately 3 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you in the world of the patient...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics